Endang Wahjunigtyas Hoyaranda

Endang Wahjunigtyas Hoyaranda

Commissioner & President Director of PT Prodia Utama (Prodia Group)

She began her career as a lecturer in Pharmaceutical and Mathematics Faculty at the Bandung Institute of Technology, prior to joining Prodia as a research and development manager in 1990. She obtained a Pharmacy Bachelor Degree in 1976 and a Pharmacist Profession at 1977 from the Bandung Institute of Technology.

Since 1990, she was appointed Operations Director of Prodia Clinical Laboratories, holding the responsibility of all operations including R&D, QA, Logistics, IT, and HR at all levels. For the period of 2002 to 2009 she was President Director of Prodia Clinical Laboratories, directing over 102 branches and a total of 218 outlets spread throughout the country. When the organization expanded into a multi-business company, she was appointed at the position of President Director of Prodia Group in 2009, which has currently 5 health-business entities operating within it, i.e. Prodia Clinical Laboratory, Prodia the CRO, Prodia Occupational Health Institute, Prodia Stemlife, Prodia Diagnostic Line and Innovasi Diagnostika. She serves as Commissioner in all those companies, including as independent commissioner in newly public listed company PT. Prodia Widyahusada Tbk.

Besides her main responsibility at Prodia, she also teaches Management, Entrepreneurship and Ethics at the Health Polytechnic and Hasanuddin University, and holds responsibility as Vice Chair at the Indonesian Institution for Laboratory Technologists Certification.

Her national professional commitments include her long dedication at the Board of the Indonesian Clinical Chemistry Association, and at the board of the Indonesian Health Laboratory Technologists Association. At the regional level, she currently holds the position of Secretary of the Asia-Pacific Federation for Clinical Biochemistry and Laboratory Medicine, and serves as Director of the Asian Association for Medical Laboratory Sciences.

In the field of drug studies, she serves at the Clinical Trial Working Group, which was pivotal in the developments of drug studies in Indonesia since 2000, and later on she became one of the founders of the Indonesian Association for the Study of Medicinals (IASMED) which was inaugurated mid 2010.